N/A N=250 Non-Complex Biliary Stones DSC vs ERC
Biliary Stones
Primary: Number of Participants With Complete Stone Clearance — 112; 108 Participants — p=0.029
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=55 Radiation Exposure of ERCP Personnel at Different Standing Locations and Different Patient Positions.
Occupational Radiation Exposure
Primary: Effective Radiation Dose — 0.0307; 0.0192 mSv
N/A N=151 Study of Forceps Cannulation During ERCP
Post-ERCP Acute Pancreatitis
Primary: Cannulation Success Rate and Difficult Cannulation Rate — 70; 68; 0; 13 Participants
N/A N=14 Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
N/A N=327 Prospective Evaluation of Biliary Tissue Sampling With ERCP
Cholangiopancreatography, Endoscopic Retrograde · Biliary Stricture · Biliary Tract Diseases
Primary: Performance Characteristics — 84.09; 56.98; 94.87 Percentage
N/A N=148 SpHincterotomy for Acute Recurrent Pancreatitis
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
N/A N=297 Spy II Clinical Registry
Biliary Tract Diseases
Primary: Procedural Success as Defined by: 1. Ability to Visualize Stricture & Obtain Biopsy of Lesion Adequate for Histological Examination in Suspected Malignancy Cases or 2…
N/A N=75 The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Management of Pancreaticobiliary Disorders
Disorders of the Pancreas and Biliary Tree
Primary: Successful Procedure Completion — 70; 5 participants
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
N/A N=88 Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS
Biliary Tract Disease
Primary: Number of Participants With Procedure Technical Success — 70; 3 participants
N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
N/A N=2,600 Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Post-ERCP Pancreatitis — 47; 100 participants
N/A N=163 Evaluation of the Impact of a Forward Viewing Scope at Time of ERCP
Gastro-Intestinal Disorder
Primary: Number of Participants With Clinically Significant Endoscopic Findings — 37 Participants
N/A N=960 Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Number of Patients Who Developed Post-ERCP Pancreatitis — 31; 32 Participants
N/A N=89 A Clinical Study With the Medical Device PowerSpiral for Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
Cholangiopancreatography, Endoscopic Retrograde
Primary: Total Success Rate. Defined as the Combined Percentage of Enteroscopy Success Rate, Biliary Cannulation Success Rate and Procedural (Therapeutic) Success Rate. — 45…
Phase 3 N=192 Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Either Elevated Amylase or Lipase 3 x Upper Limit of Normal…
N/A N=73 A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Pancreatitis
Primary: Number of Post-ERCP Pancreatitis Cases in Participants Who Are Administered Aprepitant and Placebo Prior to ERCP and One Day After ERCP:Assess the Total Number of…
N/A N=319 Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
Biliary Disease · Pancreatic Disease · Choledocholithiasis
Primary: Number of Participants With Procedure-related Adverse Events — 8; 9 Participants — p=0.8
N/A N=23 Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients
Pancreatic Cancer
Primary: S-MRCP and S-EUS Concordance
N/A N=72 Prospective Study to Investigate the Frequency of Possible Bacterial Entry Into the Bloodstream (Bacteremia) and Infectious Complications Associated With the Use of the Spyglass Cholangioscopy System During ERCP (Endoscopic Retrograde Cholangiopancreatography).
Bile Duct Stricture · Choledocholithiasis
Primary: Number of Patients With Bacteremia — 25; 20; 5; 10 Participants
N/A N=394 Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Sensitivity and Specificity of Urine Trypsinogen-2 Dipstick Testing for the Diagnosis of Post-ERCP Pancreatitis — 11.1; 91; 4.4; 96.5 percentage of participants
N/A N=117 A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis
Pancreatitis
Primary: Reduction in Pancreatitis Rate — 16.1; 4.9 percentage of participants with PEP
Phase 3 N=1,037 Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: Number of Participants Who Developed Post-ERCP Pancreatitis — 76; 65 Participants
Phase 4 N=192 Rectal Indomethacin vs Intravenous Ketorolac
Post-ERCP Acute Pancreatitis
Primary: Post-ERCP Pancreatitis — 15; 21 Participants
N/A N=56 Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP)
Conscious Sedation
Primary: Dosing Requirements — 100; 100 TOTAL DOSE OF MEPERIDINE, mg
N/A N=37 EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial
Acute Pancreatic Necrosis · Acute Pancreatitis · Necrotizing Pancreatitis
Primary: Safety: Number of Participants With Device Related Complications — 0 Participants
Phase 3 N=1,950 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: The Proportion of Subjects in Each Study Group With Post-ERCP Pancreatitis — 145; 110; 137; 90 Participants
N/A N=137 Gentamicin in Preventing Post Endoscopic Retrograde Cholangiopancreatography (ERCP) Cholangitis in Non-calculus Stenting
Cholangitis
Primary: Number of Participants With Cholangitis — 5; 5 participants — p=<0.05
N/A N=506 Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis
Pancreatitis
Primary: Post ERCP Pancreatitis is the Primary Outcome. — 26; 20 participants — p=.45
N/A N=551 Global Prospective Case Series Using a Single-Use Duodenoscope
Endoscopic Retrograde Cholangiopancreatography
Primary: Number of Participants With Successful ERCP Procedure — 529 Participants